PR Newswire
FREMONT, Calif., May 11, 2016
FREMONT, Calif., May 11, 2016 /PRNewswire/ -- Asterias
Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the
emerging field of regenerative medicine, today announced that it will release first quarter financial and operating results on
Monday, May 16, 2016 after the close of the U.S. financial markets. The Company will host a
conference call and webcast on May 16, 2016 at 4:30 p.m. Eastern /
1:30 p.m. Pacific to discuss the results and corporate developments.
For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the
call, the dial-in number in the U.S./Canada is 888-572-7025. For international participants
outside the U.S./Canada, the dial-in number is 719-325-2463. For all callers, refer to
Conference ID 3554654. To access the live webcast, go to http://asteriasbiotherapeutics.com/events-presentations/.
A replay of the conference call will be available for seven business days beginning about two hours after the conclusion of
the live call, by calling toll-free (from U.S./Canada) 888-203-1112; international callers dial
719-457-0820. Use the Conference ID 3554654. Additionally, the archived webcast will be available at http://asteriasbiotherapeutics.com/events-presentations/.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. is a leading biotechnology company in the emerging field of regenerative medicine. The
company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies.
Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high
unmet medical need in the fields of oncology and neurology. AST-VAC1 (antigen-presenting autologous dendritic cells) demonstrated
promise in a Phase 2 study in acute myelogenous leukemia (AML) and completed a successful end-of-Phase 2 meeting with the FDA in
advance of initiating planning for a single pivotal Phase 3 AML study. AST-VAC2 (antigen-presenting allogeneic dendritic
cells) represents a second generation, allogeneic immunotherapy. The company's research partner, Cancer Research UK, plans to
begin a Phase 1/2 clinical trial of AST-VAC2 in non-small cell lung cancer in 2017. AST-OPC1 (oligodendrocyte progenitor
cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. Additional information about Asterias
can be found at www.asteriasbiotherapeutics.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/asterias-biotherapeutics-to-report-first-quarter-results-on-may-16-2016-300267075.html
SOURCE Asterias Biotherapeutics, Inc.